Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Mammals have three known Gli proteins
2022-07-14

Mammals have three known Gli proteins: Gli-1, -2 and -3. Gli-1 does not undergo proteosomal degradation and hence, remains untruncated and always acts as a transcription promoter. Gli-1 is an important target gene for Gli-2. Full-length Gli-2 accumulates when Smo is activated because activated Smo p
-
Two kind systems are currently available to
2022-07-13

Two kind systems are currently available to assess the nutritional status of cancer patients, one is largely based on some subjective parameters, the other is totally based on the objective parameters. For score systems largely based on some subjective parameters, like Nutritional Risk Screening Sco
-
BQ-123 Pharmacologic approaches of inhibiting GSNOR activity
2022-07-13

Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
-
neuropeptide receptors For several years CXCL had
2022-07-13

For several years, CXCL17 had been classified as an orphan chemokine, until Maravillas-Montero et al. claimed that orphan G-coupled protein receptor GPR35 is the receptor of CXCL17 [15], [16]. However, no following research has been produced to further explore the function of the CXCL17-CXCR8 (GPR3
-
In order to investigate whether this off target activity was
2022-07-13

In order to investigate whether this off-target activity was related to a particular structural feature of this induced pluripotent stem cells or was characteristic of the series, compounds , and were selected as being matched pairs with compound but with structural variation in terms of the R,
-
Capillary monolithic columns obtained by in
2022-07-13

Capillary monolithic columns obtained by in situ polymerization have been developed rapidly as an efficient chromatographic stationary phase, which exhibits excellent reproducibility, reliable stability and fast transfer kinetics [18]. Recently, it has been extensively applied in capillary liquid ch
-
Introduction l Glutamate is a major excitatory neurotransmit
2022-07-13

Introduction l-Glutamate is a major excitatory neurotransmitter in the mammalian central nervous system (CNS) that contributes not only to fast synaptic neurotransmission, but also to complex physiological processes like memory, learning, plasticity, and neuronal cell death [30], [81]. Glutamate is
-
Furthermore we argued that an inability to
2022-07-13

Furthermore, we argued that an inability to encode or monitor the temporal sequence of events or episodes in order to discriminate between other similar or related events (encoding what-happened-when) could result in an increased susceptibility to proactive interference and, thus, in principle expla
-
This GluR A independent mechanism by which the
2022-07-13

This GluR-A-independent mechanism, by which the associative strength of spatial locations can be increased (and/or decreased) gradually over many trials, and which presumably underlies spatial reference memory acquisition during tasks such as the Morris watermaze or the radial maze (Zamanillo et al.
-
Marimastat Here we studied GLUT targeted nanomedicines as a
2022-07-13

Here, we studied GLUT1-targeted nanomedicines as a new strategy directed to overcome vascular barrier, enhancing delivery and efficacy in solid tumors. These nanomedicines were prepared by controlled installation of glucose on polymeric micelles incorporating the antitumor agent cisplatin, which is
-
br Conclusions Temporally controlled disruption of Gcgr reve
2022-07-13

Conclusions Temporally-controlled disruption of Gcgr reveals a lack meaningful contribution to the improvement of glycemic control in insulinopenic conditions attributable to the intrinsic loss of GCGR signaling. On the other hand, these data highlight the importance of compensatory systems, incl
-
br Materials and methods br Results br Discussion
2022-07-13

Materials and methods Results Discussion Importantly, we observed that treatment with DA3-CH could reduce the pathophysiological processes in the hippocampal CA1 area after SE. At present, the unimolecular dual incretin receptor agonist has been developed as a treatment for type 2 diabetes,
-
Our previous study had shown that silencing FFAR expression
2022-07-12

Our previous study had shown that silencing FFAR1 expression weakened the action of PIO in increasing insulin secretion in lipotoxic β mass of cl [6]. Resent research found that PIO promoted insulin secretion by upregulating FFAR1 [17]. Therefore, we presumed that FFAR1 may be involved in the anti-
-
Focal adhesion kinase Fakir et al
2022-07-12

Focal adhesion kinase (Fakir et al., 2006), also known as non-receptor tyrosine kinase (PTK2), is a 125-kDa protein that regulates cell migration, adhesion, proliferation, and survival (Tavora et al., 2014; Yang et al., 2016; Tian et al., 2017). Many studies have observed FAK overexpression and/or h
-
There are several basic science studies that aim to
2022-07-12

There are several basic science studies that aim to investigate potential mechanisms behind the reduced incidence of MI in factor Xa inhibitor treated patients. Perzborn et al. reported that in-vitro addition of rivaroxaban reduced tissue-factor induced platelet aggregation (Perzborn, Heitmeier, & L
15816 records 405/1055 page Previous Next First page 上5页 401402403404405 下5页 Last page